

Panacea Biotech and Serum team up for six-in-one vaccine

18 January 2018 | News

In the next two years, both companies will work together to get this vaccine introduced in the National Immunisation Programme



Panacea Biotech is research based pharmaceutical and health Management Company has signed two long-term agreements with Serum Institute of India and its wholly-owned subsidiary Bilthovan Biologicals BV, involving a fully liquid six-in-one vaccine.

Under the collaboration, Serum will be allowed to make and sell fully liquid Whole cell Pertussis (wP) and Salk-based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) developed and commercialised by Panacea Biotech.

It is the first fully liquid wP-IPV-based hexavalent vaccine in the world.

Serum Institute will ensure supply of IPV bulk to Panacea Biotech, an important constituent of the hexavalent vaccine, from its wholly-owned subsidiary Bilthovan Biologicals B V (BBIO).

Bilthovan is a bioengineering and Pharmaceutical company registered in the Netherlands; BBIO has the technology to make the IPV, earlier possessed by only three other vaccine manufacturers in the world.

In the next two years, both companies will work together to get this vaccine introduced in the National Immunisation Programme of the government and developing countries by working closely with key stakeholders.

Panacea Biotech will work with stakeholders including government of different countries, World Health Organisation (WHO), Global Alliance for Vaccines & Immunisation (GAVI), Bill and Melinda Gates Foundation (BMGF) and other United Nations agencies.